Metformin and Prostate Cancer: What is the Evidence?

Detalhes bibliográficos
Autor(a) principal: Teixeira da Silva Vieira, Catarina
Data de Publicação: 2023
Outros Autores: Monteiro, Ana Luísa, Campos, Catarina, Chão, Isabel, Gonçalves, Joana
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.29315/gm.v1i1.653
Resumo: INTRODUCTION: Prostate cancer (PCa) is the most prevalent cancer in males worldwide. Despite therapeutic advances, up to 30%-50% of patients experience recurrence. In recent years, the antineoplastic potential of metformin has been described in the incidence and prognosis of PCa. The aim of this review will be to assess the evidence on the use of metformin to reduce recurrence and increase survival in patients with PCa.METHODS: The authors carried out a literature search in evidence-based medicine databases, including articles published between 01/2010 and 05/2022, in Portuguese and English. The MeSH terms used were “metformin”, “prostate cancer” and “therapy”. The level of evidence and strength of recommendation were assigned according to the Strength Of Recommendation Taxonomy (SORT) scale.RESULTS: In the initial search, 17 articles were obtained, of which 3 meta-analyses were selected to carry out this review. All meta-analyses revealed a decrease in PCa recurrence in patients using metformin. The 3 meta-analyses also found an improvement in overall and PCa-specific survival in patients treated with metformin, however, only one of them showed a statistically significant association.CONCLUSION: This review concluded, with a strength of recommendation B, that the use of metformin may have a positive impact on reducing recurrence and improving the survival of patients with PCa. However, it will be necessary to carry out more studies, with greater robustness and quality, to confirm this relationship.
id RCAP_83961700aa892e0eae03fd6c9d45747f
oai_identifier_str oai:ojs.pkp.sfu.ca:article/653
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str
spelling Metformin and Prostate Cancer: What is the Evidence?Metformina e Cancro da Próstata: Qual a Evidência?Metformina/usoterapêuticoNeoplasias da Próstata/mortalidadeNeoplasias da Próstata/ tratamento farmacológicoMetformin/therapeutic useProstatic Neoplasms/drug therapyProstatic Neoplasms/mortalityINTRODUCTION: Prostate cancer (PCa) is the most prevalent cancer in males worldwide. Despite therapeutic advances, up to 30%-50% of patients experience recurrence. In recent years, the antineoplastic potential of metformin has been described in the incidence and prognosis of PCa. The aim of this review will be to assess the evidence on the use of metformin to reduce recurrence and increase survival in patients with PCa.METHODS: The authors carried out a literature search in evidence-based medicine databases, including articles published between 01/2010 and 05/2022, in Portuguese and English. The MeSH terms used were “metformin”, “prostate cancer” and “therapy”. The level of evidence and strength of recommendation were assigned according to the Strength Of Recommendation Taxonomy (SORT) scale.RESULTS: In the initial search, 17 articles were obtained, of which 3 meta-analyses were selected to carry out this review. All meta-analyses revealed a decrease in PCa recurrence in patients using metformin. The 3 meta-analyses also found an improvement in overall and PCa-specific survival in patients treated with metformin, however, only one of them showed a statistically significant association.CONCLUSION: This review concluded, with a strength of recommendation B, that the use of metformin may have a positive impact on reducing recurrence and improving the survival of patients with PCa. However, it will be necessary to carry out more studies, with greater robustness and quality, to confirm this relationship.INTRODUÇÃO: O cancro da próstata (CaP) é a neoplasia mais prevalente no sexo masculino a nível mundial. Apesar dos avanços terapêuticos, até 30%-50% dos doentes apresentam recorrência da mesma. Nos últimos anos, tem sido descrito o potencial anti-neoplásico da metformina, nomeadamente na incidência e prognóstico do CaP. O objetivo desta revisão será avaliar a evidência sobre o uso da metformina na redução da recorrência e no aumento da sobrevivência dos doentes com CaP.MÉTODOS: As autoras realizaram uma pesquisa bibliográfica em bases de dados de medicina baseada na evidência, tendo sido incluídos artigos publicados entre 01/2010 e 05/2022, em idioma português e inglês. Os termos MeSH utilizados foram “metformin”, “prostate cancer” e “therapy”. A atribuição de nível de evidência e força de recomendação foi realizada atendendo à escala Strength Of Recommendation Taxonomy (SORT).RESULTADOS: Na pesquisa inicial obtiveram-se 17 artigos, dos quais foram selecionadas 3 meta-análises para a realização desta revisão. Todas as meta-análises revelaram uma diminuição da recorrência do CaP nos utentes a utilizar metformina. As 3 meta-análises verificaram ainda uma melhoria da sobrevivência global e específica por CaP nos utentes sob tratamento com metformina, no entanto, apenas uma delas demonstrou associação estatisticamente significativa.CONCLUSÃO: Esta revisão concluiu, com uma força de recomendação B, que a utilização de metformina poderá ter impacto positivo na redução da recorrência e na melhoria da sobrevivência dos doentes com CaP. No entanto, será necessário realizar mais estudos, com maior robustez e qualidade, para confirmar esta relação.CUF Academic Center2023-03-20info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.29315/gm.v1i1.653https://doi.org/10.29315/gm.v1i1.653Gazeta Médica; NUMBER 1 · VOLUME 10 · JANUARY/MARCH 2023; 24-30Gazeta Médica; NÚMERO 1 · VOLUME 10 · JANEIRO/MARÇO 2023; 24-302184-06282183-813510.29315/gm.v10i1reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.gazetamedica.pt/index.php/gazeta/article/view/653https://www.gazetamedica.pt/index.php/gazeta/article/view/653/414Copyright (c) 2023 Gazeta Médicahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessTeixeira da Silva Vieira, CatarinaMonteiro, Ana LuísaCampos, CatarinaChão, IsabelGonçalves, Joana2023-04-01T04:45:28ZPortal AgregadorONG
dc.title.none.fl_str_mv Metformin and Prostate Cancer: What is the Evidence?
Metformina e Cancro da Próstata: Qual a Evidência?
title Metformin and Prostate Cancer: What is the Evidence?
spellingShingle Metformin and Prostate Cancer: What is the Evidence?
Teixeira da Silva Vieira, Catarina
Metformina/usoterapêutico
Neoplasias da Próstata/mortalidade
Neoplasias da Próstata/ tratamento farmacológico
Metformin/therapeutic use
Prostatic Neoplasms/drug therapy
Prostatic Neoplasms/mortality
title_short Metformin and Prostate Cancer: What is the Evidence?
title_full Metformin and Prostate Cancer: What is the Evidence?
title_fullStr Metformin and Prostate Cancer: What is the Evidence?
title_full_unstemmed Metformin and Prostate Cancer: What is the Evidence?
title_sort Metformin and Prostate Cancer: What is the Evidence?
author Teixeira da Silva Vieira, Catarina
author_facet Teixeira da Silva Vieira, Catarina
Monteiro, Ana Luísa
Campos, Catarina
Chão, Isabel
Gonçalves, Joana
author_role author
author2 Monteiro, Ana Luísa
Campos, Catarina
Chão, Isabel
Gonçalves, Joana
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Teixeira da Silva Vieira, Catarina
Monteiro, Ana Luísa
Campos, Catarina
Chão, Isabel
Gonçalves, Joana
dc.subject.por.fl_str_mv Metformina/usoterapêutico
Neoplasias da Próstata/mortalidade
Neoplasias da Próstata/ tratamento farmacológico
Metformin/therapeutic use
Prostatic Neoplasms/drug therapy
Prostatic Neoplasms/mortality
topic Metformina/usoterapêutico
Neoplasias da Próstata/mortalidade
Neoplasias da Próstata/ tratamento farmacológico
Metformin/therapeutic use
Prostatic Neoplasms/drug therapy
Prostatic Neoplasms/mortality
description INTRODUCTION: Prostate cancer (PCa) is the most prevalent cancer in males worldwide. Despite therapeutic advances, up to 30%-50% of patients experience recurrence. In recent years, the antineoplastic potential of metformin has been described in the incidence and prognosis of PCa. The aim of this review will be to assess the evidence on the use of metformin to reduce recurrence and increase survival in patients with PCa.METHODS: The authors carried out a literature search in evidence-based medicine databases, including articles published between 01/2010 and 05/2022, in Portuguese and English. The MeSH terms used were “metformin”, “prostate cancer” and “therapy”. The level of evidence and strength of recommendation were assigned according to the Strength Of Recommendation Taxonomy (SORT) scale.RESULTS: In the initial search, 17 articles were obtained, of which 3 meta-analyses were selected to carry out this review. All meta-analyses revealed a decrease in PCa recurrence in patients using metformin. The 3 meta-analyses also found an improvement in overall and PCa-specific survival in patients treated with metformin, however, only one of them showed a statistically significant association.CONCLUSION: This review concluded, with a strength of recommendation B, that the use of metformin may have a positive impact on reducing recurrence and improving the survival of patients with PCa. However, it will be necessary to carry out more studies, with greater robustness and quality, to confirm this relationship.
publishDate 2023
dc.date.none.fl_str_mv 2023-03-20
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.29315/gm.v1i1.653
https://doi.org/10.29315/gm.v1i1.653
url https://doi.org/10.29315/gm.v1i1.653
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.gazetamedica.pt/index.php/gazeta/article/view/653
https://www.gazetamedica.pt/index.php/gazeta/article/view/653/414
dc.rights.driver.fl_str_mv Copyright (c) 2023 Gazeta Médica
http://creativecommons.org/licenses/by-nc-nd/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Gazeta Médica
http://creativecommons.org/licenses/by-nc-nd/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv CUF Academic Center
publisher.none.fl_str_mv CUF Academic Center
dc.source.none.fl_str_mv Gazeta Médica; NUMBER 1 · VOLUME 10 · JANUARY/MARCH 2023; 24-30
Gazeta Médica; NÚMERO 1 · VOLUME 10 · JANEIRO/MARÇO 2023; 24-30
2184-0628
2183-8135
10.29315/gm.v10i1
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1777302435028533248